ClinicalTrials.gg
CompletedNCT02989662Updated May 30, 2025Results posted

INIA Stress and Chronic Alcohol Interactions: Glucocorticoid Antagonists in Heavy Drinkers

A Phase 1/2 interventional study of Mifepristone and Placebo - Cap in Alcohol Use Disorder, sponsored by Johns Hopkins University. Completed at 1 site in United States. Open to participants aged 21 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-30.

Sponsored by Johns Hopkins University · Phase 1/2, Interventional, and Basic science

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
65
Allocation
Randomized
Ages
21 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 15 studies in Alcoholism by Johns Hopkins University — 7 open to participants now, 8 under way, 1 of them phase 3. Alcoholism · Johns Hopkins University.

Enrollment
13th of 15
65 · median 122
Started
2017
the only one that year
Phase 1/2
Only one
of the 15
Registered
7th of 15
by date

Among the 15 studies in Alcoholism by Johns Hopkins University, this one is the 13th largest by enrollment, is the only one that started in 2017, is the only one in phase 1/2, and was the 7th registered.

Alcoholism

1,677 studies on the registry are indexed under Alcoholism; 332 are open to participants now.

Browse Alcoholism studies →

Open to participants now

7 of the 15 studies in Alcoholism by Johns Hopkins University are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 239 Alcoholism studies recruiting now, 85 (36%) set no upper age limit and 132 (55%) stop at 75 or younger; 9 take children under 18; 64 take healthy volunteers.

This study: 21 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Alcoholism by Johns Hopkins University, or all of them as a file.
02

Study summary

In alcohol use disorder (AUD) and matched healthy control (HC) men and women, the proposed research examines the effects of MIFE, with demonstrated preclinical effects on drinking-related behaviors, compared with placebo on a breadth of alcohol-related measures. All subjects will be randomized to daily MIFE or placebo. Before and during medication, AUD and HC subjects undergo fMRI scanning measuring resting-state functional connectivity and alcohol cue-induced brain activation focused on brain reward and stress pathways. All subjects are admitted to the Clinical Research Unit; AUD subjects undergo supervised alcohol withdrawal with daily measurements of alcohol craving and symptom severity. Using validated human laboratory procedures in AUD subjects, this study will examine the effects of stress on motivation to drink and alcohol sensitivity/reward as a function of GR antagonism.

Read the detailed description

Cortisol (CORT) is a glucocorticoid hormone, often associated with response to stress and playing a key role in alcohol use and problems. First, acute alcohol administration increases CORT, which in turn amplifies the mesolimbic dopamine reward signal. Second, alcohol withdrawal elevates CORT levels in AUD compared with healthy control subjects, and CORT levels in early abstinence predict subsequent relapse to drinking. Finally, the magnitude of CORT response to external stressors predicts motivation to work for and consumption of alcohol in the human laboratory and in the natural environment. Importantly, recent studies in rodents and humans have demonstrated that blocking CORT activity using a glucocorticoid receptor (GR) antagonist reduces these effects of CORT on alcohol behaviors, indicating a causal role for glucocorticoids in these relationships. In alcohol use disorder (AUD) and matched healthy control (HC) men and women, the proposed research examines the effects of MIFE, with demonstrated preclinical effects on drinking-related behaviors, compared to placebo on a breadth of alcohol-related measures. All subjects will be randomized to daily MIFE or placebo. Before and during medication, AUD and HC subjects undergo fMRI scanning measuring resting-state functional connectivity and alcohol cue-induced brain activation focused on brain reward and stress pathways. All subjects are admitted to the Clinical Research Unit; AUD subjects undergo supervised alcohol withdrawal with daily measurements of alcohol craving and symptom severity. Using validated human laboratory procedures in AUD subjects, this study will examine the effects of stress on motivation to drink and alcohol sensitivity/reward as a function of GR antagonism. This work will help pave the way for improved pharmacotherapies that target stress and reward pathways in the brain involved in initiating and maintaining drinking.

03

Conditions studied

  • Alcohol Use Disorder

Browse trials for

04

Who can participate

Ages eligible
21 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Nontreatment seeking AUD volunteers
  • English speaking
  • healthy
  • Not pregnant or nursing

Exclusion criteria

Exclusion Criteria:

  • Women on hormonal , pregnant or nursing
  • Current health or psychiatric problems
  • Potassium level below normal
  • Any medication or health condition that is known to interact with MIFE or CORT metabolism
  • History of metal implantation that would preclude MRI scan.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
65 participants (actual)

Study arms

  • Active comparator
    Alcohol Use Disorder - Mifepristone

    Participants diagnosed with alcohol use disorder who were randomized to receive mifepristone. Mifepristone is a high affinity antagonist of the glucocorticoid receptor (GR). It is FDA approved to treatment hyperglycemia caused by high cortisol levels in adults with endogenous Cushing's syndrome.

    Drug: Mifepristone

  • Placebo comparator
    Alcohol Use Disorder - Placebo

    Participants diagnosed with alcohol use disorder who were randomized to receive placebo. This is an inactive compound which appears physically identical to active medication.

    Drug: Placebo - Cap

  • Active comparator
    Healthy Control - Mifepristone

    Healthy control participants who were randomized to receive mifepristone. Mifepristone is a high affinity antagonist of the glucocorticoid receptor (GR). It is FDA approved to treatment hyperglycemia caused by high cortisol levels in adults with endogenous Cushing's syndrome.

    Drug: Mifepristone

  • Placebo comparator
    Healthy Control - Placebo

    Healthy control participants who were randomized to receive placebo. This is an inactive compound which appears physically identical to active medication.

    Drug: Placebo - Cap

Interventions

  • Participants receive 6 doses.

    Also known as: Korlym

  • DrugPlacebo - Cap

    Participants receive 6 doses

06

What researchers measure

Primary outcomes

  1. Change in Blood Oxygen Level Dependent (BOLD) fMRI Signal for Alcohol Versus Non-alcohol Stimuli

    Participants observed alcohol and neutral cues during functional MRI (fMRI) scans. Larger numbers indicate greater activation to alcohol versus non alcohol stimuli. Mean response Pre and Post medication (mifepristone (MIFE), placebo), is measured. The greater the number the greater the reactivity to alcohol-related cues.

    Time frame: Change from baseline (Day 1) to day 4 of MIFE dosing

Secondary outcomes

  1. Mean of Alcohol Motivated Responses Made

    Participants made alcohol motivated responses with a computer mouse to earn either alcohol drinks or money. Each mouse click equaled one response. Mean of all responses made are reported.

    Time frame: single session on study day 5

  2. Alcohol Motivated Responding - Number of Drinks Earned

    Participants can earn up to 10 drinks during a 1-hr session. Each drink was the equivalent of 0.5 standard drink.

    Time frame: single session on study day 5

07

Results

Posted May 30, 2025

Participant flow

Participant flow — Overall Study
MilestoneAlcohol Use Disorder - MifepristoneAlcohol Use Disorder - PlaceboHealthy Control - MifepristoneHealthy Control - Placebo
Started4363
Completed0361
Not completed4002
Withdrew: Lost to follow-up0002
Withdrew: Physician decision3000
Withdrew: Withdrawal by subject1000

Outcome measures

PrimaryChange in Blood Oxygen Level Dependent (BOLD) fMRI Signal for Alcohol Versus Non-alcohol Stimuli

Participants observed alcohol and neutral cues during functional MRI (fMRI) scans. Larger numbers indicate greater activation to alcohol versus non alcohol stimuli. Mean response Pre and Post medication (mifepristone (MIFE), placebo), is measured. The greater the number the greater the reactivity to alcohol-related cues.

Time frame:
Change from baseline (Day 1) to day 4 of MIFE dosing
Reported as:
Mean · BOLD response
Change in Blood Oxygen Level Dependent (BOLD) fMRI Signal for Alcohol Versus Non-alcohol Stimuli
BOLD responseAlcohol Use Disorder - MifepristoneAlcohol Use Disorder - PlaceboHealthy Control - MifepristoneHealthy Control - Placebo
Amygdala, centromedian - day 1—0.267390 ± 0.1288270.040281 ± 0.0743780.058670 ± 0.128827
Amygdala, centromedian - day 4—-0.069048 ± 0.1429520.037178 ± 0.0825330.052388 ± 0.142952
Amygdala, lateral - day 1—0.091174 ± 0.1908610.151864 ± 0.1101940.099169 ± 0.190861
Amygdala, lateral - day 4—0.294417 ± 0.115607-0.021411 ± 0.0667460.126445 ± 0.115607
medial prefrontal cortex - day 1—0.044635 ± 0.287281-0.323039 ± 0.1658620.031454 ± 0.287281
medial prefrontal cortex - day 4—0.439822 ± 0.2265760.257514 ± 0.130814-0.514729 ± 0.226576
nucleus accumbens - day 1—0.138441 ± 0.1474270.131360 ± 0.0851170.262425 ± 0.147427
nucleus accumbens - day 4—0.285409 ± 0.1061530.138914 ± 0.061287-0.003538 ± 0.106153
Amygdala, superficial - day 1—0.583073 ± 0.2698510.252555 ± 0.155799-0.111622 ± 0.269851
Amygdala, superficial - day 4—0.149175 ± 0.3470080.172212 ± 0.2003450.118748 ± 0.347008
ventral tegmental area - day 1—0.405165 ± 0.2273790.566876 ± 0.131277-0.019192 ± 0.227379
ventral tegmental area - day 4—0.430387 ± 0.176868-0.150802 ± 0.1021150.104408 ± 0.176868
SecondaryMean of Alcohol Motivated Responses Made

Participants made alcohol motivated responses with a computer mouse to earn either alcohol drinks or money. Each mouse click equaled one response. Mean of all responses made are reported.

Time frame:
single session on study day 5
Reported as:
Mean · responses made
Mean of Alcohol Motivated Responses Made
responses madeAlcohol Use Disorder - MifepristoneAlcohol Use Disorder - PlaceboHealthy Control - MifepristoneHealthy Control - Placebo
Mean of Alcohol Motivated Responses Made—9517 ± 1497.6——
SecondaryAlcohol Motivated Responding - Number of Drinks Earned

Participants can earn up to 10 drinks during a 1-hr session. Each drink was the equivalent of 0.5 standard drink.

Time frame:
single session on study day 5
Reported as:
Mean · drinks earned
Alcohol Motivated Responding - Number of Drinks Earned
drinks earnedAlcohol Use Disorder - MifepristoneAlcohol Use Disorder - PlaceboHealthy Control - MifepristoneHealthy Control - Placebo
Alcohol Motivated Responding - Number of Drinks Earned—7 ± 3——

Adverse events

Collected over Up to 6 weeks post followup. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Alcohol Use Disorder - Mifepristone0/4 (0%)0/4 (0%)0/4 (0%)
Alcohol Use Disorder - Placebo0/3 (0%)0/3 (0%)0/3 (0%)
Healthy Control - Mifepristone0/6 (0%)0/6 (0%)2/6 (33.3%)
Health Control - Placebo0/3 (0%)0/3 (0%)0/3 (0%)
Most frequent other events
Most frequent other events
EventAlcohol Use Disorder - MifepristoneAlcohol Use Disorder - PlaceboHealthy Control - MifepristoneHealth Control - Placebo
RashSkin and subcutaneous tissue disorders0/40/32/60/3

Baseline characteristics

Age, Continuous
Age, Continuous(years)Alcohol Use Disorder - MifepristoneAlcohol Use Disorder - PlaceboHealthy Control - MifepristoneHealthy Control - PlaceboTotal
Mean42.3 ± 11.841.3 ± 7.138.3 ± 13.833.7 ± 8.639.1 ± 11.5
Sex: Female, Male
Sex: Female, Male(Participants)Alcohol Use Disorder - MifepristoneAlcohol Use Disorder - PlaceboHealthy Control - MifepristoneHealthy Control - PlaceboTotal
Female12104
Male315312
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Alcohol Use Disorder - MifepristoneAlcohol Use Disorder - PlaceboHealthy Control - MifepristoneHealthy Control - PlaceboTotal
American Indian or Alaska Native00000
Asian00101
Native Hawaiian or Other Pacific Islander00000
Black or African American31228
White11316
More than one race01001
Unknown or Not Reported00000
Region of Enrollment
Region of Enrollment(Participants)Alcohol Use Disorder - MifepristoneAlcohol Use Disorder - PlaceboHealthy Control - MifepristoneHealthy Control - PlaceboTotal
United States436316
08

Study locations

1 site
  • Integrated Program for Substance Abuse Research
    Baltimore, Maryland 21205, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2017 to primary completion in Jan 2024, 76 months.

Results were first posted in May 2025, 1 year 3 months after primary completion.

Of 22 phase 1/2 interventional studies under Alcoholism, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 76. This study's 76 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2016
First posted
Dec 12, 2016
StartActual
Sep 26, 2017
Primary completionActual
Jan 31, 2024
CompletionActual
Jan 31, 2024
Results first posted
May 30, 2025
Last update
May 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02989662
Responsible party
Sponsor
First posted
Dec 12, 2016
Start date
Sep 26, 2017
Primary completion
Jan 31, 2024
Completion
Jan 31, 2024
Results posted
May 30, 2025
Last update
May 30, 2025

Study contacts

Mary E McCaul, PhD
principal investigator · Johns Hopkins University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mifepristone

Start the discussion